FXYD3 was originally identified as one of the gene products (mRNAs) highly expressed in murine mammary tumors induced by the transgenic neu or ras but not induced by myc or int-2 oncogenes.
FXYD3 was originally identified as one of the gene products (mRNAs) highly expressed in murine mammary tumors induced by the transgenic neu or ras but not induced by myc or int-2 oncogenes. 1) In human, FXYD3 mRNA was overexpressed in breast cancer cell lines and primary breast cancers, 2) and also in prostate and pancreatic cancers. [3] [4] [5] Suppression of FXYD3 expression by the small interfering RNA (siRNA) or antisense transfection caused a significant decrease in cellular proliferation of prostate and pancreatic cancer cell lines, respectively. 4, 5) Therefore, FXYD3 is involved in proliferation, and is expected to be a tumor marker.
FXYD3 is a member of the "FXYD" family proteins, which consist of seven members of small proteins that have a single transmembrane segment, and share a signature sequence of four amino acids "FXYD" (Phe-Xaa-Tyr-Asp) located in the ectodomain close to the transmembrane segment. 6) Among the seven members of FXYD proteins, only FXYD2 (Na ϩ ,K ϩ -ATPase g-subunit) and FXYD3 have two isoforms which encode two proteins of different amino acid sequences, respectively. The FXYD3 short-form (FXYD3a) mRNA has an in-frame deletion of 78 nucleotides in the coding sequence compared to the FXYD3 long-form (FXYD3b) mRNA. As a result, the FXYD3b protein has 26 more amino acids in the cytoplasmic domain compared to the FXYD3a protein ( Fig. 1) . FXYD family proteins perform fine tuning of ion transport by associating with and modulating the activity of Na ϩ ,K ϩ -ATPase molecule and modifying the activity of ion channels. 2, 7) FXYD3a slightly decreased the apparent affinity both for intracellular Na ϩ (up to 40%) and extracellular K ϩ (15 to 40%) of Na ϩ ,K ϩ -ATPase whereas FXYD3b slightly increased the apparent affinity for intracellular Na ϩ (about 15%) and decreased the apparent affinity for extracellular K ϩ (up to 50%). 8, 9) Both FXYD3 isoforms induced a hyperpolarization-activated chloride current in Xenopus oocytes. 2, 9) However, physiological roles of FXYD3 isoforms have not been fully understood yet. The expression pattern of FXYD3a and FXYD3b mRNAs has not been cleared. Moreover, it remains to be clear whether the FXYD3 proteins are overexpressed in breast cancers or not. Here, we quantified FXYD3a and FXYD3b mRNAs in human normal tissues and many human cancer cell lines by quantitative reverse transcription polymerase chain reaction (RT-PCR). We prepared two kinds of antibodies against human FXYD3 protein (one antibody against both FXYD3a and 3b; the other against FXYD3b) and examined the expression pattern of FXYD3 proteins in human cancer cell lines and human breast tissues. We also suppressed the expression of FXYD3 proteins by the treatment of siRNA to study the role of FXYD3 on cellular proliferation of a breast cancer cell line, MCF-7. U343MGa, malignant mesothelioma, HMMME were obtained from RIKEN Bioresource Center (Tsukuba, Japan). Human breast cancers, ZR-75-30 and SK-BR-3 were purchased from DS Pharma Biochemical (Suita, Japan). Human breast cancer, MCF-7 and cervical cancer, HeLa were from Dr. Tabuchi in University of Toyama. Human colon cancers, HT-29 and WiDr were from Prof. Sakai in University of Toyama. Cells were cultured in media following the instructions of the cell bank, and incubated in 0% or 5% CO 2 humidified atmosphere (data not shown). Human Tissue Specimens Human breast tumor specimens were obtained from surgical resection of 20 Japanese patients in accordance with the recommendations of the Declaration of Helsinki and with the approval of ethics committee of Ritsumeikan University. Written informed consent was obtained from all the patients studied. The mean patient age at surgery was 51 years old (range, 25-78 years old). The series included 10 invasive ductal carcinomas, 2 intra-ductal carcinomas, 2 mastopathies, 4 fibroadenomas and 2 phyllodes tumors.
MATERIALS AND METHODS

Cell Lines
Antibodies An anti-human FXYD3a/3b monoclonal antibody was prepared against the C-terminal peptide KCK-FGQKSGHHPGETPPLITPGSAQS (corresponding to amino acids of 88-113) which is shared by the FXYD3a and 3b proteins (Fig. 1) . Male BALB/c mice were immunized with the peptide conjugated with keyhole limpet hemocyanin. Antiserum titer was checked by enzyme-linked immunosorbent assay (ELISA) in which the C-terminal peptide was coated on the surface of 96-well microtiter plate. Cell fusion between mouse plasmacytomas and splenocytes was performed as described previously.
10) The supernatant of hybridomas was screened by ELISA against the immunizing peptide, and subsequently by Western blotting against the total lysate of COS-7 cells transiently expressing FXYD3a and 3b. An antihuman FXYD3b polyclonal antibody was prepared against the peptide CEWRSSGEQAGRGWGSP (corresponding to amino acids of 59-74) (Fig. 1) . This peptide represents a part of cytoplasmic domain found only in the FXYD3b protein, which is deleted in the FXYD3a protein. Male BALB/c mice were immunized with the peptide conjugated with keyhole limpet hemocyanin, and antiserum titer was checked by ELISA and Western blotting as described previously.
Immunohistochemistry Human tissue samples were fixed in a formaldehyde-based fixing solution overnight at 4°C, embedded in paraffin and cut into 4-mm-thick sections. Deparaffined and rehydrated slices were subjected to antigen retrieval by boiling for 45 min in the Immunosaver (Nisshin EM, Tokyo, Japan), followed by treatment with 3% H 2 O 2 in methanol for 20 min at room temperature. Slides were washed in phosphate-buffered saline (PBS), and then sections were incubated with the anti-FXYD3a/3b monoclonal antibody overnight at 4°C. Slides were washed in PBS, and then incubated with a horseradish peroxidase-conjugated goat anti-mouse IgG (Nichirei Bioscience, Tokyo, Japan) for 30 min at room temperature. After washed with PBS, binding was detected by diaminobenzidine (DAB) solution (Nichirei Bioscience, Tokyo, Japan). The tissue sections were counterstained using hematoxylin.
cDNA Cloning Human FXYD3a (NM_005971) and FXYD3b (NM_021910) cDNAs were prepared from human stomach cDNA library (Clontech Takara Bio, Otsu, Japan) by PCR with the forward primers being 5Ј-TGAACCA-CACAGGCCAGCG-3Ј for FXYD3a and 5Ј-CTCTCAGC-CCAGCGAGATG-3Ј for FXYD3b and reverse primer being 5Ј-CTTGCGAGAGGTGAGATGAGG-3Ј for both FXYD3a and FXYD3b, respectively. The cDNA was cloned in pCRscript SK(ϩ) vector (Stratagene, Tokyo, Japan), and DNA sequence was verified by dideoxy termination method with the ABI 3100 DNA sequencer (Applied Biosystems, Tokyo, Japan). Each cDNA was cloned in pcDNA3.1(ϩ) and pcDNA3.1-mycHisB vectors, respectively, for the heterologous expression in COS-7 and HEK-293 cells.
Transfection and Construction of Stable Cell Lines HEK-293 cells were transfected with the pcDNA3.1(ϩ)-FXYD3a cDNA construct using an Effectene Transfection reagent (QIAGEN, Tokyo, Japan), and stable cell lines were selected in the presence of 0.9 mg/ml Geneticin. Single colonies were isolated, expanded, and maintained in the presence of 0.5 mg/ml Geneticin. Cloning was performed by limited dilution in 96-well microplates. For cells transfected with the pcDNA3.1(ϩ)-human FXYD3a cDNA construct, the expression of FXYD3 was primarily checked by RT-PCR.
RNA Preparation and Quantitative RT-PCR Total RNA samples from normal human tissues were obtained from BD Biosciences (Tokyo, Japan) as the Human Premium total RNAs (bladder, brain, colon, heart, liver, lung, mammary gland, pancreas, prostate, skeletal muscle, small intestine, spleen, stomach, uterus). Total RNA samples from cell lines cultured in a 60-mm dish were prepared using an RNeasy Mini kit (QIAGEN, Tokyo, Japan) following the manufacturer's instructions. In the preparation process, RNA samples were treated with RNase-free DNase to minimize contaminated genomic DNAs. Total RNA samples were reverse-transcribed by using an oligo d(T) 6 primer to prepare cDNA samples with an Omniscript RT kit (QIAGEN, Tokyo, Japan). The cDNA samples were used as templates for quantitative RT-PCR.
Quantitative RT-PCR for human FXYD3a and glyceroaldehyde 3-phosphate dehydrogenase (G3PDH) was performed using the TaqMan Universal PCR Master Mix, and the following gene-specific primers and probes, by the use of Sequence Detection System ABI Prism 7000, following the manufacturer's instructions (Applied Biosystems, Tokyo, Japan). For human FXYD3a, the forward and reverse primers were 5Ј-AGGTTGGCGGGCTCATC-3Ј and 5Ј-CATTTG-CATTTTGCACTCATGAC-3Ј, respectively, and the probe was 5Ј-FAM-TTCTGTGCGCCATGGGCATCAT-TAMRA-3Ј. For human G3PDH, the forward and reverse primers were 5Ј-AAGGACTCATGACCACAGTCCAT-3Ј and 5Ј-CCAT-CACGCCACAGTTTCC-3Ј; respectively, and the probe was 5Ј-FAM-CCATCACTGCCACCCAGAAGACTGTG-TAMRA-3Ј. Quantitative RT-PCR for human FXYD3b was performed using the CYBR Premix Ex Taq (Takara Bio, Otsu, Japan) and the following gene-specific primers. The forward and reverse primers were 5Ј-TCAGCTCTCCC-CAACAGGTG-3Ј and 5Ј-AAATTGAACAAAGAGACC-CTCT TGC-3Ј, respectively. To quantify the copy numbers of FXYD3a and 3b mRNAs, known concentrations of the pcDNA3.1(ϩ)-FXYD3a and pcDNA3.1(ϩ)-FXYD3b constructs were used for preparation of standard curves. The expression levels of FXYD3a and 3b mRNA were normalized to the expression level of G3PDH, and represented as copy number/G3PDH. Amplified PCR products for FXYD3a, 3b, and G3PDH were verified by agarose or polyacrylamide gel electrophoresis.
siRNA Transfection A siRNA for both FXYD3a and 3b (siRNA1; 5Ј-CGCCAATGACCTAGAAGATAA-3Ј) and the non-silencing control siRNA (5Ј-AATTCTCCGAACGTGT-CACGT-3Ј) were purchased from QIAGEN (Tokyo, Japan). A siRNA for FXYD3b (siRNA2; 5Ј-ATGAGTGAGTGG-AGGAGCTTT-3Ј) was purchased from NIPPON EGT (Toyama, Japan). Cells were transfected using the Lipofectamine 2000 reagent (Invitrogen, Tokyo, Japan).
Cell Proliferation Cell proliferation was evaluated by MTT assay as described elsewhere.
11) Cells were seeded in 96-well plates at a density of 2ϫ10 3 cells/well in 100 ml of complete medium. (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (MTT) was added to a final concentration of 0.25 mg/ml. After 4 h of incubation, the formazan products were solubilized with dimethyl sulfoxide (DMSO), and the optical density was measured at 570 nm.
Membrane Preparation Crude membrane fractions of the human cancer cell lines were prepared as described previously.
12) Cells cultured in a 100-mm dish were washed with PBS, and incubated with 2 ml of low ionic salt buffer composed of 0.5 mM MgCl 2 , 10 mM Tris-HCl, pH 7.4 at 0°C for 10 min. After addition of 1 mM phenylmethylsulfonyl fluoride and 0.09 units/ml aprotinin, the cells were homogenized with a Dounce homogenizer, and the homogenate was diluted with an equal volume of a solution composed of 500 mM sucrose and 10 mM Tris-HCl, pH 7.4. The homogenate was centrifuged at 800ϫg for 10 min to precipitate a fraction containing nuclei. The supernatant was centrifuged at 10000ϫg for 30 min to precipitate a fraction containing mitochondria and lysosomes. The supernatant was further centrifuged at 100000ϫg for 90 min to precipitate a microsomal fraction. The pellet was resuspended in a solution composed of 250 mM sucrose and 5 mM Tris-HCl, pH 7.4.
Western Blot Analysis Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis was performed as described elsewhere. 13) Protein samples were incubated in a sample buffer composed of 2% SDS, 10% glycerol, 2% bmeracaptoethanol, 10 mM Tris-HCl, pH 6.8 at 100°C for 3 min, and separated on the SDS-polyacrylamide gel. Western blotting was performed as described elsewhere.
14) The proteins were transferred to a nitrocellulose membrane, Hybond ECL (GE Healthcare Bioscience, Tokyo, Japan). The membranes were blocked with 4% Block Ace solution, followed by incubation with the anti-FXYD3a/3b antibody or anti-FXYD3b antibody. After incubation with a horseradish peroxidase-conjugated anti-mouse antibody, the bands were visualized with the ECLplus kit (GE Healthcare Bioscience, Tokyo, Japan) and scanned with a luminescent imaging analyzer LAS-1000plus (Fuji Film, Tokyo, Japan). NuPAGE was performed as described elsewhere. 15) Protein samples were solubilized in a NuPAGE LDS sample buffer (Invitrogen, Tokyo, Japan) and incubated at 70°C for 10 min after addition of 2% b-mercaptoethanol. Samples were subjected to 4 to 12% SDS-PAGE gradient gel (NuPAGE BisTris Gel), and electrotransferred onto polyvinylidenedifluoride (PVDF) membranes (Invitrogen, Tokyo, Japan). Subsequently, the membrane was incubated with the antibodies as described above.
Immunofluorescence Cells were fixed for 7 min in cold methanol (Ϫ20°C) and washed three times with PBS containing 0.1 mM CaCl 2 and 1 mM MgCl 2 (PBSϩ). Cells were permeabilized in a permeabilization buffer of 0.3% Triton X-100 and 0.1% BSA in PBSϩ for 15 min at room temperature. Non-specific protein binding was blocked by preincubating in a horse serum dilution buffer solution (16% horse serum, 0.3% Triton X-100, 0.9% NaCl, and 20 mM sodium phosphate buffer solution (pH 7.4) for 1 h. All antibody incubation was carried out using the horse serum dilution buffer solution. Cells were incubated overnight at room temperature with the anti-FXYD3a/3b antibody or the anti-Na ϩ ,K ϩ -ATPase a-subunit antibody (Santa Cruz, CA, U.S.A.), followed by three washes with the permeabilization buffer. The specimens were incubated with the Alexa 633-conjugated anti-mouse immunoglobulin G (IgG) secondary antibody or Texas Red-conjugated anti-rabbit IgG secondary antibody for 1 h at room temperature at a dilution of 1 : 200. After washing with PBS+ three times, immunofluorescence image was visualized using an laser scanning confocal microscope FV1000 (Olympus, Tokyo, Japan).
RESULTS
Expression Patterns of FXYD3 mRNAs in Human Cancer Cell Lines and Normal Tissues
We quantified the expression levels of FXYD3a and 3b mRNAs in human cancer cell lines and normal tissues by the quantitative RT-PCR. Figure 2A shows the results of quantitative analysis of FXYD3a and 3b mRNA expression in human cancer cell 1150 Vol. 32, No. 7 lines. Both FXYD3 mRNAs were highly expressed in breast and pancreatic cancers (MDA-MB-453, MCF-7, ZR-75-30 and T3M-4), and moderately expressed in stomach and colonic cancers (MKN-28, MKN-45, WiDr and HT-29). The expression of both FXYD3 mRNAs was low or absent in astrocytomas (U343MGa), cervical cancers (HeLa) and lung cancers (A549 and RERF-LC-AI). Figure 2B shows the results of quantitative analysis of FXYD3a and 3b mRNA expression in human normal tissues. Both FXYD3 mRNAs were highly expressed in the colons, lungs, stomachs and prostates, and moderately expressed in the pancreases, mammary glands and bladders. The expression of both FXYD3 mRNAs was low or absent in the brains, hearts, livers, spleens, kidneys, uteruses and skeletal muscles. In all human cancer cell lines and normal tissues, the expression level of FXYD3a mRNA was higher than that of FXYD3b mRNA, indicating that the major splicing transcript of FXYD3 is FXYD3a, although the ratio of FXYD3a to 3b mRNAs was variable among different cell lines and different normal tissues.
Expression of FXYD3 Proteins in Human Cancer Cell Lines
There have been several reports studying the mRNA expression of human FXYD3a variant, however, a few reports studying the expression of FXYD3 proteins. Here, we studied the expression of FXYD3 proteins in human cancer cell lines by using the anti-FXYD3a/3b and anti-FXYD3b specific antibodies. To confirm the specificity of the antibodies, NuPAGE and Western blotting were performed for the cell lysate of COS-7 cells transfected with FXYD3a and 3b cDNAs, respectively (Fig. 3A) . The former anti-FXYD3a/3b antibody recognized a single band of FXYD3a protein with an apparent molecular mass of 8 kDa, and double bands of FXYD3b protein with apparent molecular masses of 8 and 11 kDa. The antibody recognized a single band representing FXYD3a protein conjugated with a mycHis-tag with a molecular mass of 11 kDa, and double bands representing FXYD3b protein conjugated with a mycHis-tag with apparent molecular masses of 11 and 13 kDa. However, antiFXYD3b antibody recognized only the upper bands representing FXYD3b and mycHis-FXYD3b proteins with molecular masses of 11 and 13 kDa, respectively. These bands were not observed with the antibodies in the presence of antigen peptides (data not shown). The anti-FXYD3b antibody did not recognize FXYD3a protein. Subsequently, the expression of FXYD3 proteins in human cancer cell lines was studied by NuPAGE and Western blotting with these antibodies (Fig.  3B) . The anti-FXYD3a/3b antibody recognized a clear band with a molecular mass of 8 kDa in the total lysate of breast cancers, SK-BR-3, ZR-75-30, and pancreatic cancers, T3M-4. This 8 kDa band was also observed in the total lysate of breast cancers, MCF-7, MDA-MB-453, colonic cancers, HT-29, WiDr, and gastric cancers, MKN-28, MKN-45. No band was observed in the total lysate of colonic cancer, CACO-2. However, the anti-FXYD3b antibody recognized no clear band in the total lysate of these cell lines. Our results indicated that FXYD3a is a major protein product in these cancer cell lines.
Subcellular Distribution of FXYD3 Proteins in Breast Cancer Cell Lines
To determine the subcellular distribution of endogenous FXYD3 proteins, we performed immunofluorescent study of SK-BR-3 and MCF-7 cells which express relatively high levels of FXYD3 mRNAs and proteins as shown in Figs. 2A and 3B . Specificity of anti-FXYD3a/3b antibody for immunofluorecent study was confirmed by the immunostaining pattern of HEK-293 cells; mock cells and cells stably expressing FXYD3a. The anti-FXYD3a/3b antibody stained the cells expressing FXYD3a. This staining was blocked by the treatment of the antigen peptide (data not shown). This antibody labeled the cell surface and perinuclear (intracellular) portion of SK-BR-3 and MCF-7 cells (Fig. 4A) . Some part of the signal was overlapped with that of Na ϩ ,K ϩ -ATPase a-subunit. To further clarify the intracellular distribution of FXYD3 protein, MCF-7 cells were fractionated by differential centrifugation into the P1 (800ϫg pellet), P2 (10000ϫg pellet), P3 (100000ϫg pellet) and S3 (100000ϫg supernatant) fractions, and the expression of FXYD3 protein in these fractions was examined by Western blotting. FXYD3 protein was mainly observed in the P2 and P3 fractions, and slightly detected in the P1 fraction, but not observed in the S3 fraction (Fig. 4B) . These results suggest that FXYD3 proteins were expressed at the cell surface as well as in the intracellular membrane compartments.
Delay of Cell Proliferation by RNA Interferences
To study the functional role of FXYD3 overexpressed in MCF-7 cells, the cells were transfected with siRNAs, and their growth rate was examined by MTT assay. The treatment of siRNA1 (specific for both FXYD3a and 3b) suppressed mRNA expression of FXYD3a and 3b by 75% and 65%, respectively (Figs. 5A, B) . The siRNA1 transfection results in down-regulation of FXYD3 (3aϩ3b) protein synthesis as shown in Fig. 5C . The number of MCF-7 cells was significantly decreased by the treatment of siRNA1 by 26% and 40% three and four days after transfection, respectively, compared with the non-silencing control (Fig. 5D) . The treatment of siRNA2 (specific only for FXYD3b) partly suppressed mRNA expression of FXYD3b by 54% whereas it did not suppress mRNA expression of FXYD3a (Figs. 5A, B) . The siRNA2 transfection did not significantly down-regulate FXYD3 (3aϩ3b) protein synthesis (Fig. 5C ). The number of cells was not significantly decreased by the treatment of siRNA2 (Fig. 5D) .
Expression of FXYD3 Proteins in Human Breast Tissues FXYD3 mRNAs were overexpressed in human breast cancers.
2) Here we examined whether FXYD3 proteins were also overexpressed in formaldehyde-fixed breast tumor specimens by immunohistochemical analysis. FXYD3a/3b was slightly expressed in fibroadenoma (A). Its expression level was low and almost similar to that in the surrounding normal tissues. In invasive ductal carcinoma cells (B, C), expression level of FXYD3a/3b was much higher than that in the surrounding normal tissues. The expression pattern of FXYD3a/3b was divided into 2 groups, cytosoplasmic staining (B) and cytoplasmic and membrane staining (C). N represents a normal duct, and T represents tumor cells. Magnification is 400 folds, and bars represent 100 mm. antibody. All the data were summarized in Table 1 . The FXYD3 protein was highly expressed in invasive ductal carcinoma cells and intra-ductal carcinoma cells compared with the surrounding normal tissues (represented as (ϩ) in the Table 1 ). The expression pattern of FXYD3 was classified into 2 groups, C (cytoplasm) and CM (cytoplasm and membranes). In contrast, in all of the benign lesion specimens, mastopathy, fibroadenoma and phyllodes tumor, the expression level of FXYD3 protein was as low as that of the surrounding normal tissues (represented as (Ϫ) in the Table 1 ).
DISCUSSION
Human FXYD3 has two splicing variants which encode two proteins of different amino acid sequences. FXYD3a mRNA has an in-frame deletion of 78 nucleotides in the coding region compared to FXYD3b mRNA. Consequently, the FXYD3b protein has a 26-amino acid insertion in the cytoplasmic domain. However, there has been no report to compare the expression of each splicing variant so far. In the present study, we examined the expression of FXYD3a and 3b mRNAs separately in human cancer cell lines and human normal tissues by quantitative RT-PCR. We found that FXYD3a mRNA is mainly expressed in all human cancer cell lines and normal tissues (Figs. 2A, B) . It has been shown that FXYD3 mRNA was up-regulated in a subset of breast, prostate and pancreatic cancers. [2] [3] [4] [5] In addition to these reports, our results showed that FXYD3 mRNA was mainly expressed in normal mammary glands, pancreas and gastrointestinal tracts as well as these cancer cell lines.
In this study, we tried to prepare two kinds of antibodies. One was raised against the carboxy-terminal portion of FXYD3 protein which is commonly found in both FXYD3a and 3b proteins (anti-FXYD3a/3b antibody). The other was raised against the 16 amino acid residues specific for FXYD3b protein (anti-FXYD3b antibody) (Fig. 1) . Theoretically, it is expected that the molecular mass of FXYD3b protein is slightly (3 kDa) higher than that of FXYD3a protein.
In the present study of NuPAGE and Western blotting, the anti-FXYD3a/3b antibody recognized a single band representing FXYD3a protein with an apparent molecular mass of 8 kDa, and two bands representing FXYD3b protein with apparent molecular masses of 8 and 11 kDa. However, the antiFXYD3b antibody recognized only the upper band representing FXYD3b protein with an apparent molecular mass of 11 kDa (Fig. 3A) . Similar band pattern was observed in the preparations of FXYD3a and 3b proteins conjugated with the mycHis-tag. These results may suggest that FXYD3b protein was modified by the post-translational processing in which the antigenic region of the anti-FXYD3b antibody was cleaved or masked.
In the immunofluorescent study, the anti-FXYD3a/3b antibody detected endogenous FXYD3 proteins located at the cell surface as well as intracellular compartments of MCF-7 and SKBR-3 cells (Fig. 4A) . It should be noted that FXYD3 signal was located in the particulate fractions (P2 and P3 fractions in this study), but not in the cytosol fraction (S3) in the Western blotting of subcellular fractions of MCF-7 prepared by differential centrifugation (Fig. 4B) . Therefore, the FXYD3 signal likely locates at the cell surface as well as in the intracellular membrane compartments. It has been shown that the FXYD3 isoforms associate with and modulate the function of Na ϩ ,K ϩ -ATPase. 8, 9) This characteristic is common to all the members of FXYD family. In our current study, some part of FXYD3 signal overlapped with the signal of Na To examine the effect of FXYD3 protein overexpression on cell proliferation, MCF-7 cells were treated with siRNAs specific for FXYD3a and/or 3b. Treatment of a siRNA specific for both FXYD3a and 3b decreased the rate of cell proliferation whereas there was no difference in proliferation rate between the cells treated with a siRNA specific for FXYD3b and the non-silencing control (Fig. 5D ). These results suggest that FXYD3a protein is involved in cell proliferation of MCF-7. It is difficult to determine the role of FXYD3b on the proliferation of MCF-7 cells from the present results because the expression of FXYD3b protein in MCF-7 cells was too low to be studied by Western blotting, and because the siRNA2 partially knocked-down the expression of FXYD3b mRNA.
The FXYD3 protein was specifically overproduced in all the 12 breast cancer specimens; invasive ductal carcinoma and intra-ductal carcinoma, whereas the expression was very low in 8 benign lesions specimens, mastopathy, fibroadenoma and phyllodes tumor. Therefore, the anti-FXYD3a/3b antibody may be used as a potential tool for clinical diagnosis of breast cancers. The process in which the expression of FXYD3 protein was up-regulated seems to be different between the breast and pancreatic carcinomas. The FXYD3 expression was up-regulated in chronic pancreatitis tissues, early in the process of malignant transformation to pancreatic ductal carcinomas. 5) In breast cancer specimens, distribution pattern of FXYD3 expression was divided into two groups. In one group (shown as Cϩ), expression was observed mainly in the cytoplasm. In the other group (shown as CMϩ), expression was observed in the cytoplasm and at the cell surface. Similar membranous and cytoplasmic expression pattern of FXYD3 protein was previously reported in the pancreatic ductal carcinomas. 5) In MCF-7, the FXYD3 protein was distributed in the particulate fractions in the differential centrifugation although it was apparently located at the cell surface as well as in the cytoplasm in the immunofluorescent study (Figs. 4A, B) . These results may suggest that the FXYD3 protein was distributed in the intracellular membrane, and partly at the cell surface. The factors responsible for FXYD3 up-regulation and intracellular localization in breast cancers are unknown. The FXYD3 mRNA was highly expressed in murine mammary cancers induced by the transgenic neu or ras but not induced by myc or int-2 oncogenes, 1) and aberrant activation of Ras by overexpression of receptor tyrosine kinases was seen in many human breast cancers.
16) It should be noted that ras activated by mutations can induce macro-pinocytosis, leading to the formation of large, irregular primary endocytic vesicles by closure of lamellipodia generated at the ruffling membrane. 17) Intracellular localization of FXYD3 protein might be influenced by receptor tyrosine kinases and Ras signaling.
It has been shown that in Erb2/Neu-induced tumors from transgenic mice, the FXYD3 mRNA was up-regulated, and transforming growth factor (TGF)-b signaling was downregulated due to the defect of TGF-b-Receptor-I expression. 18) In a pancreatic cancer cell line, Colo-357, which has an intact TGF-b pathway, expression of FXYD3 mRNA was down-regulated by the treatment of TGF-b. 5) In mammary glands, the TGF-b pathway regulates normal ductal and alveolar development and remodeling during postlactational involution. 19, 20) The FXYD3 mRNA is also up-regulated in the period of postlactational regression in mice.
1) Therefore, TGF-b signaling cascade may be responsible for the expression of FXYD3.
In conclusion, FXYD3a is a major splicing transcript and protein of FXYD3. The FXYD3a protein is overexpressed in human breast cancers. Down-regulation of FXYD3a in breast cancer cells decreased cell proliferation rate. These results suggest that the FXYD3a protein is responsible for cell proliferation of breast cancers.
